Article
Endocrinology & Metabolism
Yan-Song Lin, Xin Zhang, Chen Wang, Yan-Qing Liu, Wen-Min Guan, Jun Liang
Summary: The long-term evaluation of apatinib in patients with radioiodine refractory differentiated thyroid cancer showed sustainable efficacy and tolerable safety profile, especially for patients with BRAF(V600E) mutation.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Oncology
Costanza Chiapponi, Milan J. M. Hartmann, Matthias Schmidt, Michael Faust, Anne M. Schultheis, Christiane J. Bruns, Hakan Alakus
Summary: The majority of patients with differentiated thyroid cancer can be effectively treated with thyroidectomy and radioiodine therapy. However, a small percentage of patients may become unresponsive to radioiodine treatment, requiring repetitive surgery as the only curative option. Despite surgery and external beam radiation, cure for cervical relapse of radioiodine refractory FTC is rare, highlighting the need for early biological markers and systemic treatments for these patients.
Article
Medicine, General & Internal
Maaike Dotinga, Dennis Vriens, Floris H. P. van Velden, Mette K. K. Stam, Jan W. T. Heemskerk, Petra Dibbets-Schneider, Martin Pool, Daphne D. D. Rietbergen, Lioe-Fee de Geus-Oei, Ellen Kapiteijn
Summary: The management of RAI-refractory DTC patients is challenging, and current standard-of-care systemic therapy with lenvatinib has frequent toxicities. This study aims to investigate the optimal duration and efficacy of lenvatinib treatment and the feasibility and safety of subsequent I-131 therapy. Identifying patients who redifferentiate after lenvatinib therapy is crucial for improving the quality of life and reducing toxicity.
Article
Endocrinology & Metabolism
C. Saie, J. Wassermann, E. Mathy, N. Chereau, L. Leenhardt, S. Tezenas du Montcel, C. Buffet
Summary: The study found that different age cutoffs have some impact on the survival and disease progression of RAIR-DTC patients, but age 65 is not a significant predictive factor for survival. Cutoffs at 45 and 75 years old were predictive for overall survival but not progression-free survival.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Chao Meng, Juanjuan Song, Wen Long, Zhuanzhuan Mu, Yuqing Sun, Jun Liang, Yansong Lin
Summary: A convenient nomogram model was developed to predict radioiodine refractory differentiated thyroid cancer. The progression of this cancer can be further stratified as rapidly or slowly progressive based on biochemical markers and age.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Medicine, General & Internal
Xian Cheng, Shichen Xu, Yun Zhu, Jing Wu, Jiandong Bao, Huixin Yu, Li Zhang
Summary: The study found that elevated preoperative thyroglobulin (pre-Tg) levels are associated with radioiodine refractory (RAIR) in patients with differentiated thyroid cancer (DTC), serving as an independent predictor. This marker can guide more precise treatment strategies and follow-up monitoring for RAIR-DTC patients.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Endocrinology & Metabolism
Wei Du, Xiangyu Shi, Qigen Fang, Xu Zhang, Shanting Liu
Summary: In the study of using apatinib to treat RAIR-DTC, patients had high objective response rate and disease control rate. The median progression-free survival and overall survival were 18 and 59 months, respectively. Adverse events were common but mostly mild to moderate.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Laura Valerio, Federica Guidoccio, Carlotta Giani, Elisa Tardelli, Giulia Puccini, Luciana Puleo, Elisa Minaldi, Giuseppe Boni, Rossella Elisei, Duccio Volterrani
Summary: The study investigated the role of [F-18]-FDG-PET/CT in evaluating metabolic response and predicting outcomes in RAI-R DTC patients treated with lenvatinib. Results showed that 57.6% of patients had the best metabolic response at the first [F-18]-FDG-PET/CT scan after 4 weeks of treatment, with a correlation between metabolic response and biochemical response. Patients with a metabolic response at [F-18]-FDG-PET/CT had longer overall survival.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Mathematics
Araceli Gago-Arias, Sara Neira, Filippo Terragni, Juan Pardo-Montero
Summary: A mechanistic biomathematical model of molecular radiotherapy for thyroid disease was presented, incorporating differential equations to describe the dynamics of different cell populations and treatment response indicators. The model comes in two flavors for fitting population data and investigating tumor control probabilities and treatment individualization strategies. Simple individualization strategies based on absorbed dose and tumor radiosensitivity show potential for improving tumor control probabilities.
Article
Oncology
Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, Marie Attard, Claire Bournaud, Ludovic Lacroix, Danielle Benisvy, David Taieb, Stephane Bardet, Marie Terroir-Cassou-Mounat, Nadege Anizan, Emilie Bouvier-Morel, Livia Lamartina, Georges Lion, Sarah Betrian, Christophe Sajous, Aurelie Schiazza, Marie-Eve Garcia, Renaud Ciappuccini, Martin Schlumberger, Abir Al Ghuzlan, Yan Godbert, Isabelle Borget
Summary: Dabrafenib-trametinib is effective for restoring iodine uptake in BRAF p.V600E-mutated DTC patients, with a 6-month partial response observed in 38% of patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Laura Boucai, Mahesh Saqcena, Fengshen Kuo, Ravinder K. Grewal, Nicholas Socci, Jeffrey A. Knauf, Gnana P. Krishnamoorthy, Mabel Ryder, Alan L. Ho, Ronald A. Ghossein, Luc G. T. Morris, Venkatraman Seshan, James A. Fagin
Summary: The determinants of response or resistance to radio-iodine (RAI) are unknown. The study aimed to identify genomic and transcriptomic factors associated with structural responses to RAI treatment of metastatic thyroid cancer. It was found that high MAPK pathway output was associated with RAI refractoriness. ER tumors have a lower MAPK output and higher TDS than NR, whereas NR have a high frequency of BRAFV600E and 1q-gain. Molecular profiling of thyroid cancers may help predict response to RAI therapy.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Petra Petranovic Ovcaricek, Alfredo Campenni, Bart de Keizer, Desiree Deandreis, Michael C. Kreissl, Alexis Vrachimis, Murat Tuncel, Luca Giovanella
Summary: Radioiodine therapy is the main treatment for metastatic differentiated thyroid cancer, but only half of the patients achieve remission or have stable disease during follow-up. Novel tracers like PSMA ligands and FAPI have potential for diagnosing and treating radioiodine-refractory disease. This review discusses the role of these radiopharmaceuticals in managing radioiodine-refractory disease.
Article
Health Care Sciences & Services
Genpeng Li, Wenjie Chen, Yanping Gong, Tao Wei, Rixiang Gong, Jingqiang Zhu, Zhihui Li, Jianyong Lei
Summary: This study found that circulating exosomal miRNAs, particularly miR-1296-5p, may be involved in the pathogenesis of radioiodine refractory papillary thyroid carcinoma (RAIR PTC) by directly targeting NIS.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Cell Biology
Thoudam Debraj Singh, Jae Eon Lee, Kwang Hee Son, Bo Ra Lee, Sang Kyoon Kim, Deepak Gulwani, Vijaya Sarangthem, Yong Hyun Jeon
Summary: In this study, we found that the inverse agonist of ERR gamma, GSK5182, enhances NIS function by modulating ERR gamma and MAP kinase signaling, leading to increased responsiveness to radioiodine in RAI-refractory papillary thyroid cancer cells.
Article
Oncology
Marina Muzza, Gabriele Pogliaghi, Carla Colombo, Erika Carbone, Valentina Cirello, Sonia Palazzo, Francesco Frattini, Davide Gentilini, Giacomo Gazzano, Luca Persani, Laura Fugazzola
Summary: Oxidative stress is found to play a role in the pathogenesis and progression of thyroid cancer. Thyroid tumors exhibit higher levels of oxidative stress compared to normal tissues. The degree of oxidative stress is inversely correlated with tumor differentiation and directly correlated with somatic mutations, tumor presentation, and aggressiveness.
Review
Oncology
B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G. Zarkavelis, C. Zielinski, P. Zygoura, N. Cherny
Summary: ESMO-MCBS is a widely used tool for evaluating the clinical benefit of cancer drugs, but may have shortcomings in addressing biases generated by flawed design, implementation, or data analysis. Future iterations of ESMO-MCBS will address these issues.
Article
Oncology
Rebecca J. Lee, Oskar Wysocki, Cong Zhou, Rohan Shotton, Ann Tivey, Louise Lever, Joshua Woodcock, Laurence Albiges, Angelos Angelakas, Dirk Arnold, Theingi Aung, Kathryn Banfill, Mark Baxter, Fabrice Barlesi, Arnaud Bayle, Benjamin Besse, Talvinder Bhogal, Hayley Boyce, Fiona Britton, Antonio Calles, Luis Castelo-Branco, Ellen Copson, Adina E. Croitoru, Sourbha S. Dani, Elena Dickens, Leonie Eastlake, Paul Fitzpatrick, Stephanie Foulon, Henrik Frederiksen, Hannah Frost, Sarju Ganatra, Spyridon Gennatas, Andreas Glenthoj, Fabio Gomes, Donna M. Graham, Christina Hague, Kevin Harrington, Michelle Harrison, Laura Horsley, Richard Hoskins, Prerana Huddar, Zoe Hudson, Lasse H. Jakobsen, Nalinie Joharatnam-Hogan, Sam Khan, Umair T. Khan, Khurum Khan, Christophe Massard, Alec Maynard, Hayley McKenzie, Olivier Michielin, Anne C. Mosenthal, Berta Obispo, Rushin Patel, George Pentheroudakis, Solange Peters, Kimberly Rieger-Christ, Timothy Robinson, Jacobo Rogado, Emanuela Romano, Michael Rowe, Marina Sekacheva, Roseleen Sheehan, Julie Stevenson, Alexander Stockdale, Anne Thomas, Lance Turtle, David Vinal, Jamie Weaver, Sophie Williams, Caroline Wilson, Carlo Palmieri, Donal Landers, Timothy Cooksley, Caroline Dive, Andre Freitas, Anne C. Armstrong
Summary: The study aimed to develop a decision support tool to assist in hospital admission decisions and predict the severity of COVID-19 in cancer patients. The results showed that the CORONET model could effectively predict the need for hospital admission and the severity of the disease, and it was validated in healthcare systems worldwide.
JCO CLINICAL CANCER INFORMATICS
(2022)
Article
Oncology
Oskar Wysocki, Cong Zhou, Jacobo Rogado, Prerana Huddar, Rohan Shotton, Ann Tivey, Laurence Albiges, Angelos Angelakas, Dirk Arnold, Theingi Aung, Kathryn Banfill, Mark Baxter, Fabrice Barlesi, Arnaud Bayle, Benjamin Besse, Talvinder Bhogal, Hayley Boyce, Fiona Britton, Antonio Calles, Luis Castelo-Branco, Ellen Copson, Adina Croitoru, Sourbha S. Dani, Elena Dickens, Leonie Eastlake, Paul Fitzpatrick, Stephanie Foulon, Henrik Frederiksen, Sarju Ganatra, Spyridon Gennatas, Andreas Glenthoj, Fabio Gomes, Donna M. Graham, Christina Hague, Kevin Harrington, Michelle Harrison, Laura Horsley, Richard Hoskins, Zoe Hudson, Lasse H. Jakobsen, Nalinie Joharatnam-Hogan, Sam Khan, Umair T. Khan, Khurum Khan, Alexandra Lewis, Christophe Massard, Alec Maynard, Hayley McKenzie, Olivier Michielin, Anne C. Mosenthal, Berta Obispo, Carlo Palmieri, Rushin Patel, George Pentheroudakis, Solange Peters, Kimberly Rieger-Christ, Timothy Robinson, Emanuela Romano, Michael Rowe, Marina Sekacheva, Roseleen Sheehan, Alexander Stockdale, Anne Thomas, Lance Turtle, David Vinal, Jamie Weaver, Sophie Williams, Caroline Wilson, Caroline Dive, Donal Landers, Timothy Cooksley, Andre Freitas, Anne C. Armstrong, Rebecca J. Lee
Summary: Indicators of COVID-19 severity in cancer patients remain predictive across different waves of the pandemic. Vaccination and steroid use have contributed to improved outcomes. The CORONET model performs well regardless of SARS-CoV-2 variants.
Article
Oncology
Vicente Escudero-Vilaplana, Lorena Romero-Medrano, Cristina Villanueva-Bueno, Marta Rodriguez de Diago, Alberto Yanez-Montesdeoca, Roberto Collado-Borrell, Juan Jose Campana-Montes, Belen Marzal-Alfaro, Jose Luis Revuelta-Herrero, Antonio Calles, Mar Galera, Rosa alvarez, Ana Herranz, Maria Sanjurjo, Antonio Artes-Rodriguez
Summary: This project aims to develop a mobile app that continuously records smartphone parameters to assess patients' health status and quality of life. Phase 1 focused on developing the app and evaluating its usability and satisfaction among patients. The app was found to be intuitive and helpful by a majority of patients, indicating good acceptability and satisfaction.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Jair Bar, Nir Peled, Shiruyeh Schokrpur, Mirjana Wolner, Ofer Rotem, Nicolas Girard, Frank Aboubakar Nana, Sofie Derijcke, Waleed Kian, Sandip Patel, Hadas Gantz-Sorotsky, Alona Zer, Mor Moskovitz, Giulio Metro, Yakir Rottenberg, Antonio Calles, Maximilian Hochmair, Kristof Cuppens, Lynn Decoster, Martin Reck, Dror Limon, Estelamari Rodriguez, Christoforos Astaras, Adrienne Bettini, Simon Hafliger, Alfredo Addeo
Summary: This study aimed to collect real-world data on osimertinib treatment for patients with uncommon EGFR mutations (ucEGFRmuts). The results showed that osimertinib has a high rate of disease control, both systemically and intracranially, in patients with ucEGFRmuts. The study also identified several resistance mechanisms.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Thiago Quinaglia, Carlos Gongora, Magid Awadalla, Malek Z. O. Hassan, Amna Zafar, Zsofia D. Drobni, Syed S. Mahmood, Lili Zhang, Otavio R. Coelho-Filho, Giselle A. Suero-Abreu, Muhammad A. Rizvi, Gagan Sahni, Anant Mandawat, Eduardo Zatarain-Nicolas, Michael Mahmoudi, Ryan Sullivan, Sarju Ganatra, Lucie M. Heinzerling, Franck Thuny, Stephane Ederhy, Hannah K. Gilman, Supraja Sama, Sofia Nikolaidou, Ana Gonzalez Mansilla, Antonio Calles, Marcella Cabral, Francisco Fernandez-Aviles, Juan Jose Gavira, Nahikari Salterain Gonzalez, Manuel Garcia de Yebenes Castro, Ana Barac, Jonathan Afilalo, Daniel A. Zlotoff, Leyre Zubiri, Kerry L. Reynolds, Richard Devereux, Judy Hung, Michael H. Picard, Eric H. Yang, Dipti Gupta, Caroline Michel, Alexander R. Lyon, Carol L. Chen, Anju Nohria, Michael G. Fradley, Paaladinesh Thavendiranathan, Tomas G. Neilan
Summary: GCS and GRS are reduced in patients with ICI myocarditis, and the magnitude of reduction has prognostic significance.
JACC-CARDIOVASCULAR IMAGING
(2022)
Article
Oncology
Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, Wael Zrafi, Nicole Conci, Giacomo Massa, Giulio Metro, Isabelle Monnet, Patricia Gomez Iranzo, Fabrizio Tabbo, Emilio Bria, Florian Guisier, Damien Vasseur, Colin R. Lindsay, Santiago Ponce-Aix, Sophie Cousin, Fabrizio Citarella, Vincent Fallet, Jose Nicolas Minatta, Anna Eisert, Hortense de Saint Basile, Clarisse Audigier-Valette, Laura Mezquita, Antonio Calles, Giannis Mountzios, Marco Tagliamento, Jordi Remon Masip, Judith Raimbourg, Safae Terrisse, Alessandro Russo, Diego Cortinovis, Philippe Rochigneux, David James Pinato, Alessio Cortellini, Camille Leonce, Anas Gazzah, Maria-Rosa Ghigna, Roberto Ferrara, Filippo Gustavo Dall'Olio, Francesco Passiglia, Vienna Ludovini, Fabrice Barlesi, Enriqueta Felip, David Planchard, Benjamin Besse
Summary: This retrospective study analyzed 218 cases of non-small cell lung cancer (NSCLC) with RET fusion mutations and found that RET inhibitors can significantly improve patient survival, while immune checkpoint inhibitors may also be effective in some patients.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Miguel Garcia-Pardo, Inmaculada Aparicio, Inigo Martinez, Marta Arregui, Victoria Tirado, Mar Galera, Rosa Alvarez, Antonio Calles
Summary: Plasma-based next-generation sequencing can potentially identify additional driver alterations in patients with NSCLC compared to single-gene testing. Identifying driver alterations in plasma helps NSCLC patients receive matched targeted therapy, leading to better outcomes. Further studies are needed to explore the cost-effectiveness of liquid biopsy and novel strategies.
CLINICAL LUNG CANCER
(2023)
Article
Health Care Sciences & Services
Maria Presa, David Vicente, Antonio Calles, Laura Salinas-Ortega, Jaesh Naik, Luis F. Garcia, Javier Soto
Summary: This study evaluated the efficiency of lorlatinib compared to alectinib and brigatinib for the treatment of ALK-positive advanced NSCLC patients. The results suggest that lorlatinib may be a more efficient treatment option compared to alectinib and potentially compared to brigatinib.
CLINICOECONOMICS AND OUTCOMES RESEARCH
(2023)
Meeting Abstract
Oncology
Rachel E. Sanborn, Saiama N. Waqar, Byoung Chul Cho, Benjamin Besse, Koichi Goto, Yongsheng Wang, Se-Hoon Lee, Melina E. Marmarelis, Yuichiro Ohe, Dong-Wan Kim, Antonio Calles, Joel Neal, Christina S. Baik, Pasi A. Janne, Joshua C. Curtin, Bharvin Patel, Mike Gormley, S. Martin Shreeve, Joshua M. Bauml, Roland E. Knoblauch
Article
Hematology
Inmaculada Aparicio, Patricia Iranzo, Roxana Reyes, Helena Bote, Maria Saigi, Marianela Bringas, Joaquim Bosch-Barrera, Jesus Corral, Francisco Aparisi, Jose C. Ruffinelli, Beatriz Jimenez, Yolanda Lage, Rafael Lopez-Castro, Margarita Majem, Sergio Vazquez, Angel Artal, Angel Rodriguez-Perez, Martin Lazaro-Quintela, Jose Miguel Sanchez Torres, Noemi Reguart, Marc Cucurull, Ignacio Gil-Bazo, Carlos Camps, Ernest Nadalj, Anabel del Barrio, Pilar Garrido, Manuel Domine, Rosa Alvarez, Andres J. Munoz, Antonio Calles
Summary: This study aimed to determine if advanced BRAF-mutant NSCLC has a higher thromboembolic events (TEE) rate. The study found that approximately 30% of patients experienced TEE, suggesting that systematic anticoagulation should be offered to these patients. However, there was no significant association between clinical and molecular features, as well as cancer treatment, and TEE occurrence.
THROMBOSIS RESEARCH
(2023)
Meeting Abstract
Oncology
Mihaela Aldea, Arianna Marinello, Wael Zrafi, Fabrizio Tabbo, Florian Guisier, Damien Vasseur, Vincent Fallet, Clarisse Audigier-Valette, Laura Mezquita, Antonio Calles, Giannis Mountzios, Marco Tagliamento, Judith Raimbourg, Safae Terrisse, Silvia Novello, Maria-Rosa Ghigna, Fabrice Barlesi, David Planchard, Benjamin Besse
Meeting Abstract
Oncology
Jair Bar, Nir Peled, Shiruyeh Schokrpur, Elizabeth Dudnik, Mira Wollner, Nicolas Girard, Frank Aboubakar Nana, Sofie Derijcke, Waleed Kian, Sandip P. Patel, Hadas Yocheved Gantz Sorotsky, Alona Zer, Mor Moskovitz, Giulio Metro, Yakir Rottenberg, Antonio Calles, Maximilian Hochmair, Kristof Cuppens, Lynn Decoster, Alfredo Addeo
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Antonio Calles, Alejandro Navarro, Bernard Doger, Maria J. de Miguel, Rosa Maria Alvarez Alvarez, Victor Moreno, Jorge Ramon, Maria del Mar Galera Lopez, Tatiana Hernandez-Guerrero, Elena Corral, Emiliano Calvo
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Z. G. Andric, G. Galffy, M. Cobo Dols, B. Szima, G. Stojanovic, M. D. Petrovic, E. Felip Font, D. Vicente Baz, S. Ponce Aix, O. Juan-Vidal, S. Tehenes, Z. Szalai, G. Losonczy, A. Calles Blanco, R. Bernabe, K. Duecker, D. Zhou, A. Schroeder, G. Guezel, F. Ciardiello
JOURNAL OF THORACIC ONCOLOGY
(2021)